T argeting of R enal C ell C a rc in o m a W ith Labeled C h im e ric M o n o c lo n a l A n tib o d y G250 Purpose: Pharmacokinetics, biodistribution, immunogenicity, and imaging characteristics of iodine 131 (,31l)-labeled chimeric monoclonal antibody (mAb) G 250 (cG250) were studied in patients with renal cell carci noma (RCC) to determine the therapeutic potential of this antibody.
Patients and Methods: Sixteen patients with RCC re ceived a single intravenous (IV) infusion of 6 mCi 131l-labeled cG250. Five protein dose levels w ere investi gated (2 to 50 mg). Planar scintigraphic images w ere acquired, and normal tissue biopsies and tumor samples w ere obtained at surgery (7 days postinjection). The immunogenicity of cG250 was investigated using a sand wich enzyme*'Kinked immunosorbent assay (ELISA) and dosimetric analysis was performed.
Results: In all patients with antigen-positive tumors (n = 13)^ the prim ary tumors and all known metastases w ere clearly visualized. Overall uptake, expressed as the percentage of the injected dose (%ID), in the prim ary tumors ranged from 2 .4 to 9.0. Focally, 131l-cG250 up-R ENAL CELL CARCINOMA (RCC) is the most common malignant disease of the adult kidney, and accounts for 80% to 90% of all primary kidney neo plasms.1 Approximately 30% to 40% of all patients pres ent with metastatic disease at the time of diagnosis,2 The treatment of choice for RCC patients without clinical apparent metastatic disease is radical nephrectomy. How ever, about one third of these patients develop metastases after surgery, usually within 1 year. For these patients, as well as for patients with advanced disease, the 5-year survival rate is less than 10% and the median survival time is less than 2 years.2 Given such a poor prognosis, there is need for a more effective treatment for RCC patients following radical nephrectomy.
Since the development of hybridoma technology by Köhler and Milstein,3 therapeutic approaches using monoclonal antibodies (mAbs) have been investigated in tensely. Nevertheless, their therapeutic promise still needs fulfillment. In patients with primary RCC, excellent tumor targeting of iodine 131 (131I)-labeled murine mAb G250 (mG250) was shown.4 In a subsequent activity dose-escalation study with 13,I-mG250 in patients with metastasized RCC, a few minor responses were observed.5 Although mG250 seemed a suitable vehicle for radioimmunother apy, the occurrence of human antimouse antibodies (HAMA) in all patients studied hampered the use of mG250 for multiple-treatment radioimmunotherapy, which was possibly necessary to obtain durable re sponses. To minimize the occurrence of HAMA, a chitake as high as 0.52% ID /g was observed. H ow ever, intratum oral uptake was highly heterogeneous. 1311-cG250 uptake in nontumorous tissues rem ained low . Do simetric analysis showed that up to .4 8 G y/m C i was guided to the prim ary tumors. Selected " hot a re a s " within these tumors received up to .7 2 G y/m C i. A bone metastasis received .23 G y/m C i and regional lymph node metastases received .2 0 G y/m C i. M inim al human antichimeric antibody (HACA) levels w ere detected in two of 16 patients.
Conclusion: 131l-cG 250 tumor uptake is am ong the highest reported in clinical studies with antitum or an ti bodies in solid tumors. Since tumor-sterilizing levels m ay be guided to the tumor w hen high doses 131l-cG 250 are administered (> 100 mCi) and cG 250 appears to be immunosilent, cG250 is a promising vehicle for radioim m u notherapy in RCC.
J Clin Oncof 1 5 :1 5 2 9 " 1537. © 1 9 9 7 b y Am erican So ciety o f Clinical Oncology. * merized version of mAb G250 (cG250) has been devel oped. In this study, we report on a clinical phase I protein dose-escalation trial with 13,I-labeled cG250 performed to determine the safety of a single intravenous (IV) infu sion. The in vivo behavior in terms of pharmacokinetics, biodistribution, immunogenicity, and imaging character istics of this chimerized antibody as compared with its murine progenitor was studied in patients with primary RCC. In addition, dosimetry was performed to estimate the radiation absorbed dose that was guided to RCC le sions and organs at risk to determine the therapeutic po tential of 13,I-cG250.
PATIENTS AND METHODS

Patient Characteristics
Sixteen patients with a clinical diagnosis of primary RCC were studied: 10 men, age 46 to 80 years (mean, 59), and six women, The generation, characteristics, and reactivity of mAb mG250 have been described earlier. 6 In summary, mAb G250 is reactive with the antigen G250, expressed in all clear cell RCCs and the majority of non-clear cell RCCs. Expression in normal organs is restricted to the gastric mucosal cells and the larger bile ducts. mAb cG250 immunoglobulin G1 (Ig G l) has been produced by DNA re combinant technology as described by Velders et al.7 Essentially, the constant regions of heavy and light chains of mAb mG250 were substituted by their human analogs.
The cG250 antigen-binding specificity was studied in vitro in a competitive binding assay. Briefly, I25I-labeled mG250 was incu bated with 106 G25O-expressing RC-SK-52 cells (a human RCC cell line kindly provided by Dr L.J. Old, Memorial Sloan-Kettering Cancer Center, New York, NY) and increasing amounts of either unlabeled cG250 or unlabeled mG250, Cells were incubated for 4 hours at room temperature. Subsequently, the cell suspension was centrifuged and the activity associated with the cell pellet measured in a gamma counter (1480 Wizard 3"; Wallac Oy, Turku, Finland).
The affinity constant (K") of cG250 was determined in a Scatchard analysis on RC-SK-52 cells as described previously.8
R a d io la b e lin g a n d Q u a lity C o n tro l
Sterile vials with purified and pyrogen-free, clinical grade cG250 were generously provided by Centocor Europe B V, Leiden, the Neth erlands. mAb cG250 was labeled according to the Iodogen (Pierce Chemical Co, Rockford, IL) method.9 Briefly, 0.4 mL cG250 (5 mg/ mL) and 100 fiL 0.5-mol/L sodium phosphate (pH 7.2) were added to an iodogen-coated tube (50 fig). Subsequently, 10 mCi sodium (Na)i3!I (Nordion, Fleur us, Belgium) was added. After 10 to 15 minutes of incubation at room temperature, the reaction mixture was applied on a PD 10 column (Pharmacia, Woerden, the Netherlands) and eluted with phosphate-buffered Saline (PBS). The first activity peak eluted from the PD 10 column was collected and cold cG250 was added to obtain the desired amount cG250 protein labeled with 6 mCi 1311. Instant thin-layer chromatography (ITLC) was used to determine the presence of free 13'1 and the immunoreactive fraction of each preparation was determined on freshly trypsinized SK-RC-52 cells as described previously.8
Study D e sig n Before the antibody injection, the medical history of each patient was taken and a physical examination was performed. To block 13lI uptake in the thyroid, patients received 100 mg potassium iodide two times daily and 200 mg potassium perchlorate four times daily, starting 24 hours before administration of the radiolabeled antibody. This regimen was continued until surgery. Five protein dose levels of cG250 were investigated (2, 5, 10, 25, and 50 mg) with at least three patients per dose level.13lI-cG250 in 0.9% sodium chloride (NaCl) (total volume, 10 to 20 mL) was administered IV over a 20-minute period. Vital signs were measured frequently and blood samples were drawn just before the antibody administration and at later time points until surgery. Whole-body images were recorded 1, 24, 48, 96, or 120 and 144 or 168 hours postinjection using a dual-headed gamma camera (Multispect 2; Siemens Inc, Hoffman Estates, IL) equipped with a high-energy collimator. At surgery (1 week postinjection), a tumor nephrectomy was performed and biop sies of normal tissue (skin, fat, muscle, peritoneum, and liver) were obtained. All primary tumors were cut in slices of 1-cm thickness. The slices were imaged directly on a single-head gamma camera (Orbiter; Siemens Inc) equipped with a high-energy collimator. Us ing the images, tumor samples (1 cm3), including high and low uptake areas, were selected from a tumor slice. Tissues were weighed and the 1311 content was measured in a gamma counter. l3,I-cG250 blood levels and tumor and normal tissue uptake were expressed as the percentage of the injected dose per gram of tissue (%ID/g). The half-life of disappearance from the blood was calculated by nonlinear least-square regression analysis.
Im m uno h is to c hem is tty
Antigen expression was determined by immunohistochemistry on a number of selected tumor samples. Briefly, 4-fim cryostat sections of snap-frozen tumor biopsies were acetone-fixed, washed, incubated for 1 hour at room temperature with 100 ¡XL of 10 /xg/mL mAb mG250, washed, reacted with peroxidase-labeled rabbit antimouse Ig (RAMPO; DAKO, Carpentina, CA), washed, and developed with 3-3'-diaminobenzidine/0.03% hydrogen peroxide (H20 2). Antigen expression was scored as follows: less than 5% cells positive; -b, 5% to 50% cells positive; ++, 50% to 95% cells positive; and + + -1 -, greater than 95% cells positive.
D e te rm in a tio n o f H u m a n A n tic h im e ric A ntibody
Responses
The immunogenicity of cG250 was investigated in serum samples of all patients obtained before and 1, 3, 6, and 12 weeks after infusion. A sandwich enzyme-linked immunosorbent assay (ELISA) was developed in which cG250 was used as catcher antibody and biodnylated cG250 as tracer antibody. Biotinylation of cG250 was performed according to the manufacturer's instructions (Pierce Eu rope, Oud Beijerland, the Netherlands). Wells of 96-well microtiter After another wash (PBS/1 % BSA, three times), wells were incu bated with streptavidin-biotinylated horseradish peroxidase complex for 30 minutes at 37°C (Amersham, Little Chalfond, United King dom). Wells were washed (PBS/1 % BSA, three times) and developed with 3,3\5,5'-tetramethylbenzidine/H20 2 (100 ¿¿L, 20 minutes at room temperature). The reaction was stopped by adding 100 jiL 2.5-mol/L sulfuric acid (H2S 04). Optical density was measured at 450 am. Proven human antimouse antibody (HAMA)-positive sera from patients who participated in previous trials with mG250 were used as positive controls (a kind gift of Dr N.H. Bander, New York Hospital, New York, NY). Serial dilutions of antiidiotype antibody NUH-82 Ig G l10 were used to obtain a standard curve. The detection lim it of the assay was 25 ng NUH-82/mL. To define further the epitopes of the cG250 Ig G l molecule against which a human anti chimeric antibody (HACA) response might be directed, sera that were positive in the sandwich ELISA as described earlier were investigated in two similar ELIS As, as follows; (1) mG250 IgG l as catcher/tracer antibody to determine any response against the murine part of cG250, and (2) chimeric M O v l8 (a mAb reactive with an ovarian cancer-associated antigen) with the same human constant regions as cG250 was used as catcher antibody and biotinylated cG250 as tracer antibody to detect reactivity directed against the human part of cG250.
Dosimetiy
Dosimetric analysis was performed in 10 patients (two patients at each dose level). The conjugated views counting technique for the whole-body images was used to quantitate 13,I-cG250 uptake in selected organs.11 Briefly, regions of interest (ROI) over the tumor, whole body, chest, total abdomen, pelvis, liver, spleen, and extremi ties were drawn on anterior and posterior view images recorded at all five time points. The differences in attenuation between the thorax, extremities, and abdomen were determined using a 1311 transmission flood source. The geometric mean of anterior and posterior counts was calculated after correction for differences in attenuation. After background subtraction and correction for physical decay, absolute retention of activity in a RO I was calculated via comparison with the activity of the total-body scintigram directly after infusion. Data were expressed as a percentage o f the total injected dose (%ID). Radiation-absorbed doses to the tumor and to organs of interest were calculated with the MIRDOSE3 program. 12
RESULTS
Affinity, Immiuio re activity, Radiolabeling, and Quality Con tro I
To evaluate whether chimerization of mAb G250 had affected the binding characteristics of the antibody, com petitive binding assays were performed. Competition analysis showed that unlabeled cG250 was at least equally effective in displacing L25I-mG250 as unlabeled mG250. The IC30 of mG250 was 1,100 pmol/L and the inhibition concentration5o (IQo) of cG250 was 700 pmoi/L (data not shown). The affinity constants (K J of both mG250 and cG250 as determined in a Scatchard analysis were identical with a Ka = 4 X 109 mol/L'1.
The efficiency of the radioiodination reaction, ie, the per centage of 131I added to die reaction that was bound to the antibody, varied between 65% and 80%. After PD 10 elu tion, ITLC showed that greater tiian 99% of the pooled radioactivity was protein-bound (release criterium > 95%).
The mean immunoreactive fraction of the mI-cG250
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• ■ 1 . preparations was 95% ± 5%. In two patients, the imrnunoreactive fraction of plasma I31I activity was monitored up to 1 week postinjection and at least 80% of the circulat ing 13'1 activity was shown to be immunoreactive for the investigated period (0 to 7 days postinjection).
Clinical Observations
The injection of the radiolabeled antibody was tolerated well by all patients and no side effects were seen. No significant changes in vital signs, hematologic, or blood chemistry parameters were observed.
Pharmacokinetics
The mean blood clearance curves from patients with G250-positive tumors at the various dose levels are shown in Fig 1. Curves fitted a two-comp ailment model. The half-life of the distribution phase (t1/2a:) was similar at all protein dose levels (t 1/2a = 3.8 ± 2.0 hours). In contrast, the half-life of the elimination phase (t1/2/3) differed sig nificantly between the 2-mg and the higher protein dose levels. At the 2 mg protein dose level, tmp was signifi cantly lower (ti/2)3 = 39.6 ± 9.6 hours) as compared with the other, higher protein dose levels (UnP ~ 68.5 ± 13.5 hours) (P < .005). Mean overall cumulative excretion in the urine in 7 days was 59.9% ± 12.9% ID, which indi cates that the primary route of radiolabel excretion was via the kidneys.
Imaging
Excellent visualization of primary tumors was obtained in all 13 patients with G250 antigen-positive tumors. In Ant.
Post. general, tumors lesions were visualized from 1 day post injection onwards. Due to the background clearance of I31I'CG250, image quality improved with time. In some cases studied at the lower protein dose levels (2 and 5 mg)} bowel activity complicated interpretation of the images. All metastatic lesions (five) as identified by ultra sound, computed tomography, or x-ray, were visualized: one bone (patient no. 2, Fig 2) , one pulmonary (patient no. 4), one brain (patient no. 12), one vaginal (patient no. 9), and multiple regional lymph node metastases (patient no. 8, Fig 3) .
At higher protein dose levels (25 and 50 mg), tumor accumulation was less pronounced, and as a consequence, tumor images were less clear as compared with images at the lower protein dose levels. Nevertheless, tumors were still well delineated at the higher protein dose levels.
As was observed with mG250,4 liver uptake was more pronounced at the 2-mg dose level as compared with the higher protein dose levels (Fig 2) .
Bio distribution
Extensive tumor sampling and sampling of selected normal tissues 8 days postinjection was performed to de termine the absolute uptake of l3!I-cG250 ( Table 2 ). The overall uptake in the tumorous kidneys (including the remaining normal kidney tissue and perirenal fat) ranged from 2.4% to 9.0% ID. Most of these tumorous kidneys were large, with a weight greater than 1,000 g (range, 300 to 1,700 g), and some contained large areas with extensive necrosis. Therefore, 1-cm3 samples were taken from viable tumor areas and the radioactivity in each sample was determined separately. In most antigen-posi tive tumors, considerable differences in regional tumor uptake, up to two orders of magnitude, were observed * (Fig 4) . In three tumors (patients no. 1, 9, and 16), focal tumor uptake was greater than 0.1% ID/g. The highest focal tumor uptake was found in the primary tumor of patient no. 16 (5-mg dose): 0.5233% ID/g. In the primary tumors of patients who received 25 or 50 mg cG250, tumor uptake was not greater than 0.0170% ID/g, while at the lower protein doses, higher focal uptake was found. Uptake in a cluster of tumor-positive lymph nodes (pa tient no, 8) was 0.0136% ID/g. Uptake in necrotic areas remained low and was not greater than 0.0015% ID/g. cG250 uptake in antigen-negative tumors was not greater than 0.0040% ID/g (range, 0.0005% to 0.0040% ID/g; Table 2 ).
Activity measurements of the liver biopsies (all patients with antigen-positive tumors) confirmed the enhanced liver uptake, as noted on the images, at the lower protein dose levels (0.0034% ± 0.0020% ID/g at 2-mg dose and 0.0017% ± 0.0002% ID/g at 5-mg dose) as compared with the liver uptake at the higher protein dose levels (0,0009% ± 0.0003% ID/g). Assuming a total liver mass of 1,5 kg, liver uptake at the 2-mg dose accounted for 5.1% of the total injected dose, while at the higher protein dose levels (10, 25, and 50 mg), liver uptake accounted for 1.4% of the total injected dose.
HACA Responses
In two patients (no. 7 and 8), a HACA response could be detected in the sera obtained at 12 weeks postinjection as determined by sandwich ELISA with cG250 as catcher/ tracer antibody. HACA responses were not detectable in sera obtained earlier than 12 weeks postinjection and HACA levels in these two patients were low, with a maximum equivalent of 300 ng/mL NUH-82, whereas the positive control sera (from patients who participated in trials with mG250) showed HAMA levels up to 36,000 ng/mL NUH-82. Follow-up serum samples, drawn at 20 weeks postinjection, showed that the HACA responses in these two patients did not increase. Further analysis of these HACA responses with the ELIS As using (1) murine G250 as catcher/tracer antibody and (2) chimeric MOvl8 as catcher/cG250 as tracer antibody showed that these responses were not directed against the human part of the cG250 IgG molecule.
In the preinjection serum sample of patient no. 9, pre existing antibodies reactive with both mG250 and cG250 were detected (300 ng NUH-82/mL).
Dosimetiy
Dosimetric analysis performed in 10 patients (two pa tients per dose level) showed that the radiation-absorbed dose to the G250-positive primary tumors ranged from .06 (patient no. 1, 2-mg dose) to .48 Gy/mCi (patient no. 16, 5-mg dose). As considerable tumor heterogeneity was observed, which was partially a reflection of tumor necro sis, radiation-absorbed dose estimates were also calcu lated for selected " hot areas" within these primary tu mors. This analysis showed that considerably higher radiation-absorbed doses were guided to these areas (Ta ble 3). The highest amount of radioactivity was delivered to a tumor thrombus, which received .72 Gy/ mCi (patient no. 16, 5-mg dose, Fig 5) . More importantly, dosimetric analysis of metastatic lesions showed that a bone metasta sis received .23 Gy/mCi (patient no. 2, 2-rng dose) and regional lymph node metastases received .20 Gy/mCi (pa tient no. 8, 10~mg dose). Calculation of the mean radiation-absorbed dose to or gans at risk indicated that .17 ± .08 Gy/mCi was delivered to the thyroid, the liver received .04 ± .01 Gy/mCi, and the bone marrow received .011 ± .003 Gy/mCi.
DISCUSSION
A phase I protein dose-escalation study was performed to determine the pharmacokinetics, toxicity, immunogenicity, and imaging characteristics of l3lI-labeled mAb cG250 in patients with RCC. Previous studies have indicated that mAb mG250 may have considerable therapeutic potential as a vehicle for radioirmmmotherapy 4,5 provided the strong H A M A responses can be circumvented. Multiple doses are probably needed to produce any lasting responses in radio immunotherapy. Chimerization resulted in a major decrease of the immunogenicity of this antibody: minimal HACA responses were detected in only two patients as determined by cG250 sandwich ELISA. No measurable immune re sponses were detected against the human part of cG250. The minimal, presumably clinically nonrelevant HACA re sponses, observed in two of 16 patients, illustrate the highly reduced immunogenicity of cG250 as compared with its murine progenitor. Therefore, multiple treatments with cG250 seem feasible. These observations are in accordance with (lie results of other studies: Meredith et al1 3 showed that chimerization of mAb 17-1A highly reduced the immu nogenicity and Buist et al1 4 found similar results with chime ric mAb MOvl.8.
The in vitro binding characteristics of cG250 were similar to those of mG250, which demonstrates that chimerization of the antibody did not affect specificity, affinity, or avidity. In general, die in vivo behavior, including the half-life (tI«/?), of cG250 was comparable to mG250 ( t|aft cG250 68.5 hours v t\ n(3 mG250 47 hours). The first chimerized antibodies, eg, chimeric mAb 17-1 A 1 3 and chimeric mAb B72.3,15 showed much longer half-lives in patients than their murine progenitors, which resulted in relatively poor tumor/ nontumor ratios, considered a disadvantage in radioimmu notherapy. However, other chimerized antibodies, eg, chi meric mAb MOvI8,16 chimeric anticarcinoembryonic anti gen (anti-CEA) antibodies,1 7 and chimeric mAb LL2,1S have shown half-lives similar to their murine counterpart, as was observed for mAb cG250.
Antigen-mediated tumor uptake of ,3lI-cG250 was demonstrated by the difference in uptake between anti gen-positive versus antigen-negative tumors: uptake in samples of antigen-negative tumors (7 days postinjection) was not greater than 0.0040% ID/g (blood 7 days postin jection, 0.0042% ID/g), while uptake in antigen-positive tumors was as high as 0.5233% ID/g (blood, 0.0028% ID/g). Extensive sampling of the primary tumors showed that regional differences in tumor uptake were as high as two orders of magnitude. This observed heterogeneity was much more pronounced at the 2-, 5-, and 10-mg dose levels as compared with the 25-and 50-mg dose levels. In addition, tumor uptake greater than 0.1% ID/g was observed only at the 2-, 5-, and 10-ing dose levels, while maximum uptake at the 25-and 50-mg dose levels was 0.0170% ID/g and 0.0120% ID/g, respectively. These ob-Ant.
Post. servations suggest a saturation of accessible G250 epi topes in the tumor at the higher protein doses. In the study with mG250, a similar relative decrease in tumor uptake with increasing protein dose was observed.4 In contrast, in investigations with other anti tumor antibodies, doses of 10 mg/kg or greater have been administered without any indication of tumor saturation. 1 C J,2°S aturable, anti gen-mediated liver uptake was observed with cG250, similar to mG250.4 This liver uptake is in accordance with the known antigen expression on the larger bile ducts.6 Assuming a liver weight of 1,500 g, mean liver uptake at the 2-mg dose level accounted for 5.1 % of the total injected dose, while at the higher protein closes (10, 25, and 50 mg) mean liver uptake accounted for 1.4% of the total injected dose. At the 2-mg protein dose level, blood clearance was faster as compared with the other protein dose levels. This might be the result of enhanced hepatic uptake at this lower protein dose level, since the hepatic compartment absorbed a relatively high amount of cG250 at 2 mg protein as compared with higher protein dose levels. Furthermore, higher excretion of 13ll in the bile as a result from this hepatic uptake may also explain the observed bowel activity at the lower protein dose levels.
All antigen-positive primary tumors, as well as all met astatic lesions, as identified by conventional imaging techniques, were visualized. Bander et al21 reported 90% successful imaging of primary RCC sites with l31I-mG250. Additionally, occult lesions, confirmed at surgery were visualized. In our study, no additional lesions were detected. Larger studies are needed to evaluate the diag nostic potential of mAb G250 as an imaging agent.
Radioimmunotherapy is most likely to be effective in metastasized patients with a relatively low tumor burden. In RCC patients with recurrent or metastasized disease, radioimmunotherapy might be applied as a second-line therapeutic modality, since no other effective therapy is available. Dosimetric analyses indicated that radiationabsorbed doses ranging from .06 to .48 Gy/mCi were guided to the primary tumors. More importantly, a num ber of regional lymph node metastases received .20 Gy/ mCi and a bone metastasis received .23 Gy/mCi. In solid tumors, responses of radioimmunotherapy can be expected when radiation-absorbed doses greater than 50 Gy are delivered to the tumor lesions,22'24 For bone marrow, 2 Gy is considered to be the maximum-tolerated radiation dose in radioimmunotherapy.23'25 Assuming the bone mar row to be the dose-limiting organ, doses as high as 200 mCi l3lI-cG250 can be administered safely. Thus radiation-absorbed doses close to tumor-sterilizing levels seem achievable. Furthermore, single high-dose radioimmuno therapy with bone marrow support or multiple dosing, either with or without bone marrow support, may be nec essary to achieve major responses. With both approaches, considerable higher radioactivity doses can be adminis tered,19,26
In conclusion, cG250 seems to be a good candidate for radioimmunotherapy of RCC. The highly reduced immu nogenicity opens the possibility of multiple-treatment therapy. Further studies with cG250 are warranted to in vestigate whether this approach will lead to an effective therapy for patients with metastasized RCC.
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